These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29561053)

  • 1. Label-free detection of β-amyloid peptides (Aβ40 and Aβ42): a colorimetric sensor array for plasma monitoring of Alzheimer's disease.
    Ghasemi F; Hormozi-Nezhad MR; Mahmoudi M
    Nanoscale; 2018 Apr; 10(14):6361-6368. PubMed ID: 29561053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
    Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
    Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
    Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
    J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.
    Kim HJ; Park KW; Kim TE; Im JY; Shin HS; Kim S; Lee DH; Ye BS; Kim JH; Kim EJ; Park KH; Han HJ; Jeong JH; Choi SH; Park SA
    J Alzheimers Dis; 2015; 48(4):1043-50. PubMed ID: 26444752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.
    Chatterjee P; Elmi M; Goozee K; Shah T; Sohrabi HR; Dias CB; Pedrini S; Shen K; Asih PR; Dave P; Taddei K; Vanderstichele H; Zetterberg H; Blennow K; Martins RN
    J Alzheimers Dis; 2019; 71(3):775-783. PubMed ID: 31424403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplex immunoassay measurement of amyloid-β
    Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
    Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.
    Blennow K; De Meyer G; Hansson O; Minthon L; Wallin A; Zetterberg H; Lewczuk P; Vanderstichele H; Vanmechelen E; Kornhuber J; Wiltfang J; ; Heuser I; Maier W; Luckhaus C; Rüther E; Hüll M; Jahn H; Gertz HJ; Frölich L; Hampel H; Pernetzki R
    J Nutr Health Aging; 2009 Mar; 13(3):205-8. PubMed ID: 19262954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An optimized UPLC-MS/MS method for human plasma amyloid-β 42 and 40 measurement and application in Alzheimer's disease diagnosis.
    Zhang Q; Bai K; Jin X; Zhan M; Han L; Zhuang J; Huang X
    J Pharm Biomed Anal; 2024 Nov; 250():116396. PubMed ID: 39128283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple Colorimetric Detection of Amyloid β-peptide (1-40) based on Aggregation of Gold Nanoparticles in the Presence of Copper Ions.
    Zhou Y; Dong H; Liu L; Xu M
    Small; 2015 May; 11(18):2144-9. PubMed ID: 25641831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New plasma LC-MS/MS assays for the quantitation of beta-amyloid peptides and identification of apolipoprotein E proteoforms for Alzheimer's disease risk assessment.
    Weber DM; Kim JC; Goldman SM; Clarke NJ; Racke MK
    J Investig Med; 2024 Jun; 72(5):465-474. PubMed ID: 38548482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine.
    Basun H; Nilsberth C; Eckman C; Lannfelt L; Younkin S
    Dement Geriatr Cogn Disord; 2002; 14(3):156-60. PubMed ID: 12218259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
    Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I
    Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical Histories of Control Subjects Influence the Biomarker Potential of Plasma Aβ in Alzheimer's Disease: a Meta-analysis.
    Zhang S; Huang SY; An XB; Zeng L; Ai J
    J Mol Neurosci; 2020 Jun; 70(6):861-870. PubMed ID: 32125624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in plasma Aß peptides and onset of dementia in adults with Down syndrome.
    Schupf N; Zigman WB; Tang MX; Pang D; Mayeux R; Mehta P; Silverman W
    Neurology; 2010 Nov; 75(18):1639-44. PubMed ID: 21041786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reaction Kinetics-Mediated Control over Silver Nanogap Shells as Surface-Enhanced Raman Scattering Nanoprobes for Detection of Alzheimer's Disease Biomarkers.
    Yang JK; Hwang IJ; Cha MG; Kim HI; Yim D; Jeong DH; Lee YS; Kim JH
    Small; 2019 May; 15(19):e1900613. PubMed ID: 30957959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma.
    Pérez-Grijalba V; Fandos N; Canudas J; Insua D; Casabona D; Lacosta AM; Montañés M; Pesini P; Sarasa M
    J Alzheimers Dis; 2016 Sep; 54(2):751-62. PubMed ID: 27567833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma concentrations of free amyloid β cannot predict the development of Alzheimer's disease.
    Lövheim H; Elgh F; Johansson A; Zetterberg H; Blennow K; Hallmans G; Eriksson S
    Alzheimers Dement; 2017 Jul; 13(7):778-782. PubMed ID: 28073031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma amyloid beta levels and platelet mitochondrial respiration in patients with Alzheimer's disease.
    Fišar Z; Jirák R; Zvěřová M; Setnička V; Habartová L; Hroudová J; Vaníčková Z; Raboch J
    Clin Biochem; 2019 Oct; 72():71-80. PubMed ID: 30954436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma Amyloid-β Peptides in Type 2 Diabetes: A Matched Case-Control Study.
    Peters KE; Davis WA; Taddei K; Martins RN; Masters CL; Davis TM; Bruce DG
    J Alzheimers Dis; 2017; 56(3):1127-1133. PubMed ID: 28106562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevation of Plasma Amyloid-β Level is More Significant in Early Stage of Cognitive Impairment: A Population-Based Cross-Sectional Study.
    Wang J; Qiao F; Shang S; Li P; Chen C; Dang L; Jiang Y; Huo K; Deng M; Wang J; Qu Q
    J Alzheimers Dis; 2018; 64(1):61-69. PubMed ID: 29865072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.